Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    April 2019
  1. WRIGHT AK, Kontopantelis E, Emsley R, Buchan IE, et al
    Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: A Population-Based Cohort Study Assessing Sex Disparities.
    Circulation. 2019 Apr 15. doi: 10.1161/CIRCULATIONAHA.118.039100.
    PubMed     Text format     Abstract available


  2. SATTAR N, Rawshani A, Franzen S, Rawshani A, et al
    Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks Findings From the Swedish National Diabetes Registry.
    Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.037885.
    PubMed     Text format    


  3. LOW WANG CC, Everett BM, Burman KD, Wilson PWF, et al
    Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
    Circulation. 2019;139:1741-1743.
    PubMed     Text format    


    March 2019
  4. FURTADO RHM, Bonaca MP, Raz I, Zelniker TA, et al
    Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039996.
    PubMed     Text format     Abstract available


  5. KATO ET, Silverman MG, Mosenzon O, Zelniker TA, et al
    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.040130.
    PubMed     Text format     Abstract available


  6. FIGTREE GA, Radholm K, Barrett TD, Perkovic V, et al
    Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.
    Circulation. 2019 Mar 17. doi: 10.1161/CIRCULATIONAHA.119.040057.
    PubMed     Text format     Abstract available


    February 2019
  7. RAWSHANI A, Rawshani A, Sattar N, Franzen S, et al
    Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes.
    Circulation. 2019 Feb 25. doi: 10.1161/CIRCULATIONAHA.118.037454.
    PubMed     Text format     Abstract available


  8. FERDINAND KC, Izzo JL, Lee J, Meng L, et al
    Antihyperglycemic and Blood Pressure Effects of Empagliflozin in African Americans with Type 2 Diabetes and Hypertension.
    Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.036568.
    PubMed     Text format     Abstract available


  9. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of
    Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.038868.
    PubMed     Text format     Abstract available


  10. KIDOKORO K, Cherney DZI, Bozovic A, Nagasu H, et al
    Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging.
    Circulation. 2019 Feb 18. doi: 10.1161/CIRCULATIONAHA.118.037418.
    PubMed     Text format     Abstract available


  11. PETRIE JR, Sattar N
    Excess Cardiovascular Risk in Type 1 Diabetes Mellitus.
    Circulation. 2019;139:744-747.
    PubMed     Text format    


    January 2019
  12. WU S, Lu Q, Ding Y, Wu Y, et al
    Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase alpha2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes in vivo.
    Circulation. 2019 Jan 16. doi: 10.1161/CIRCULATIONAHA.118.033552.
    PubMed     Text format     Abstract available


  13. FIGTREE GA, Radholm K, Neal B
    Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:418-419.
    PubMed     Text format    


  14. KOH KK
    Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:416-417.
    PubMed     Text format    


  15. GREENE SJ, Butler J
    Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019;139:152-154.
    PubMed     Text format    


    December 2018
  16. BJORNSTAD P, Schafer M, Truong U, Cree-Green M, et al
    Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.
    Circulation. 2018;138:2895-2907.
    PubMed     Text format     Abstract available


  17. MANN JFE, Fonseca V, Mosenzon O, Raz I, et al
    Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Circulation. 2018;138:2908-2918.
    PubMed     Text format     Abstract available


  18. VERMA S, Poulter NR, Bhatt DL, Bain SC, et al
    Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
    Circulation. 2018;138:2884-2894.
    PubMed     Text format     Abstract available


    November 2018
  19. KARIO K, Okada K, Kato M, Nishizawa M, et al
    24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
    Circulation. 2018 Nov 29. doi: 10.1161/CIRCULATIONAHA.118.037076.
    PubMed     Text format     Abstract available


  20. SOUSA GR, Pober D, Galderisi A, Lv H, et al
    Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus: A DCCT/EDIC Cohort-Based Study.
    Circulation. 2018 Nov 26. doi: 10.1161/CIRCULATIONAHA.118.036068.
    PubMed     Text format     Abstract available


  21. MCGUIRE DK, Alexander JH, Johansen OE, Perkovic V, et al
    Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038352.
    PubMed     Text format     Abstract available


    October 2018
  22. DONZELLI A, Schivalocchi A, Giudicatti G
    Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effica
    Circulation. 2018;138:1912-1913.
    PubMed     Text format    


  23. KOH KK
    Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy Internat
    Circulation. 2018;138:1914-1915.
    PubMed     Text format    


  24. VERMA S, Leiter LA, Mazer CD, Bain SC, et al
    Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Circulation. 2018;138:1605-1607.
    PubMed     Text format    


  25. CLAGGETT B, Lachin JM, Hantel S, Fitchett D, et al
    Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
    Circulation. 2018;138:1599-1601.
    PubMed     Text format    


    August 2018
  26. TAMPAKIS A, Tampaki EC, Gurke L
    Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:848-849.
    PubMed     Text format    


  27. WANNER C, von Eynatten M, Zinman B
    Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:850-851.
    PubMed     Text format    


  28. KOH KK
    Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:846-847.
    PubMed     Text format    


    July 2018
  29. SATTAR N, McGuire DK
    Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
    Circulation. 2018;138:7-9.
    PubMed     Text format    


    June 2018
  30. MCALLISTER DA, Read S, Kerssens J, Livingstone S, et al
    Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes.
    Circulation. 2018 Jun 27. pii: CIRCULATIONAHA.118.034986.
    PubMed     Text format     Abstract available


  31. YOUNG LH, Viscoli CM, Schwartz GG, Inzucchi SE, et al
    Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
    Circulation. 2018 Jun 22. pii: CIRCULATIONAHA.118.034763.
    PubMed     Text format     Abstract available


    May 2018
  32. VERMA S, Bhatt DL, Bain SC, Buse JB, et al
    Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Circulation. 2018;137:2179-2183.
    PubMed     Text format    


  33. PACKER M
    Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1981-1982.
    PubMed     Text format    


  34. GAZMURI RJ, Karmazyn M
    Letter by Gazmuri and Karmazyn Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1979-1980.
    PubMed     Text format    


    April 2018
  35. HU L, Qi Z, Zhang S, Luo X, et al
    Response by Hu et al to Letters Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1877-1878.
    PubMed     Text format    


  36. GONG L, Li J, Yang G
    Letter by Gong et al Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1875-1876.
    PubMed     Text format    


  37. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1874.
    PubMed     Text format    


    March 2018
  38. RADHOLM K, Figtree G, Perkovic V, Solomon SD, et al
    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Circulation. 2018 Mar 11. pii: CIRCULATIONAHA.118.034222.
    PubMed     Text format     Abstract available


  39. VIJAYAKUMAR S, Vaduganathan M, Butler J
    Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.
    Circulation. 2018;137:1060-1073.
    PubMed     Text format     Abstract available


    January 2018
  40. IANIRO G, Cammarota G, Gasbarrini A
    Letter by Ianiro et al Regarding Article, "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium".
    Circulation. 2018;137:213-214.
    PubMed     Text format    


  41. PLUTZKY J, Bakris G
    Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
    Circulation. 2018;137:130-133.
    PubMed     Text format    


    December 2017
  42. GIUGLIANO RP, Cannon CP, Blazing MA, Nicolau JC, et al
    Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
    Circulation. 2017 Dec 20. pii: CIRCULATIONAHA.117.030950.
    PubMed     Text format     Abstract available


    November 2017
  43. VERMA S, Mazer CD, Al-Omran M, Inzucchi SE, et al
    Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.032031.
    PubMed     Text format     Abstract available


    October 2017
  44. LYTVYN Y, Bjornstad P, Udell JA, Lovshin JA, et al
    Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Circulation. 2017;136:1643-1658.
    PubMed     Text format     Abstract available


  45. YOUNG LH, Viscoli CM, Inzucchi SE, Kernan WN, et al
    Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1567-1568.
    PubMed     Text format    


  46. JIN-SHAN H, Xue-Bin L
    Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1565-1566.
    PubMed     Text format    


  47. MUSSO G, Cassader M, Gambino R
    Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1563-1564.
    PubMed     Text format    


  48. WOLSK E, Claggett B, Diaz R, Dickstein K, et al
    Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1560-1562.
    PubMed     Text format    


  49. PACKER M
    Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
    Circulation. 2017;136:1548-1559.
    PubMed     Text format     Abstract available


  50. BUTLER J, Anker SD
    The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Circulation. 2017;136:1459-1461.
    PubMed     Text format    


    September 2017
  51. WILSON PWF, Gagnon D
    Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors: A Challenge to Improve Usual Care.
    Circulation. 2017;136:1204-1206.
    PubMed     Text format    


  52. STRIEPE K, Jumar A, Ott C, Karg MV, et al
    Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1167-1169.
    PubMed     Text format    


  53. WANNER C, Lachin JM, Inzucchi SE, Fitchett D, et al
    Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.
    Circulation. 2017 Sep 13. pii: CIRCULATIONAHA.117.028268.
    PubMed     Text format     Abstract available


    August 2017
  54. NAUCK MA, Meier JJ, Cavender MA, Abd El Aziz M, et al
    Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Circulation. 2017;136:849-870.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: